Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay-Reference-Cited by-同舟云学术

Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay

Published:2018-08 Issue:8 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

de Miranda Silva Carolina¹,Hajihosseini Amirhossein¹,Myrick Jenny²,Nole Jocelyn²,Louie Arnold²,Schmidt Stephan¹,Drusano George L.²

Affiliation:

1. Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, Florida, USA

2. Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA

Abstract

Tuberculosis is the ninth-leading cause of death worldwide. Treatment success is approximately 80% for susceptible strains and decreases to 30% for extensively resistant strains.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00856-18

Reference30 articles.

1. World Health Organization. 2017. Chapter 3, TB disease burden, p 21–62. Global tuberculosis report 2017. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/, Accessed 23 March 2018.

2. World Health Organization. 2017. Chapter 4 Diagnosis and treatment: TB HIV-associated TB and drug-resistant TB p 63–96. Global tuberculosis report 2017. World Health Organization Geneva Switzerland. http://www.who.int/tb/publications/global_report/en/. Accessed 23 March 2018.

3. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis

4. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS;Selkon JB;Bull World Health Organ,1964

5. The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Mechanistic Approach to Optimize Combination Antibiotic Therapy;2024-06-11

3. Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype;Antimicrobial Agents and Chemotherapy;2022-10-18

4. Pre-Clinical Tools for Predicting Drug Efficacy in Treatment of Tuberculosis;Microorganisms;2022-02-26

5. Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase;Antimicrobial Agents and Chemotherapy;2021-09-17